Conversion therapy for unresectable hepatocellular carcinoma after lenvatinib: Three case reports

INTRODUCTION: Lenvatinib (LEN) is a novel potent multi-tyrosine kinase inhibitor, approved as first-line treatment for unresectable hepatocellular carcinoma (HCC). Considering its high objective response rate, LEN therapy could be expected to achieve downstaging of tumors and lead to conversion ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomonari, Tetsu, Sato, Yasushi, Tanaka, Hironori, Tanaka, Takahiro, Taniguchi, Tatsuya, Sogabe, Masahiro, Okamoto, Koichi, Miyamoto, Hiroshi, Muguruma, Naoki, Saito, Yu, Imura, Satoru, Bando, Yoshimi, Shimada, Mitsuo, Takayama, Tetsuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7571946/
https://www.ncbi.nlm.nih.gov/pubmed/33080748
http://dx.doi.org/10.1097/MD.0000000000022782

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7571946/
https://www.ncbi.nlm.nih.gov/pubmed/33080748
http://dx.doi.org/10.1097/MD.0000000000022782

Ejemplares similares